公开(公告)号：US20230002381A1

公开(公告)日：2023-01-05

申请号：US17850650

申请日：2022-06-27

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Yu CHEN ,  Michael SACCO ,  James LEAHY ,  Elena BRAY ,  Xingmin SUN ,  Xiujun ZHANG

IPC: C07D471/08 ,  A61K45/06

Abstract: Disclosed herein are compounds that can prevent and treat C. difficile by inhibiting sporulation. Also disclosed herein are compositions and formulations comprising the compound disclosed herein. Methods of preventing and treating C. difficile comprising administering the compounds described herein are also disclosed.

公开(公告)号：US20240207359A1

公开(公告)日：2024-06-27

申请号：US18421775

申请日：2024-01-24

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Jung A. WOO ,  Stephen Bryant LIGGETT ,  David E. KANG ,  Yu CHEN ,  Eric LEWANDOWSKI

IPC: A61K38/17 ,  A61K31/42 ,  A61K31/437 ,  A61K31/496 ,  A61P25/28

CPC classification number: A61K38/1709 ,  A61K31/42 ,  A61K31/437 ,  A61K31/496 ,  A61P25/28

Abstract: As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.

公开(公告)号：US20240051959A1

公开(公告)日：2024-02-15

申请号：US18376525

申请日：2023-10-04

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Yu CHEN ,  Michael SACCO ,  James LEAHY ,  Elena BRAY ,  Xingmin SUN ,  Xiujun ZHANG

IPC: C07D471/08 ,  A61K45/06

CPC classification number: C07D471/08 ,  A61K45/06

Abstract: Disclosed herein are compounds that can prevent and treat C. difficile by inhibiting sporulation. Also disclosed herein are compositions and formulations comprising the compound disclosed herein. Methods of preventing and treating C. difficile comprising administering the compounds described herein are also disclosed.

公开(公告)号：US20230116783A1

公开(公告)日：2023-04-13

申请号：US17798041

申请日：2021-02-08

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Jung A. WOO ,  Stephen Bryant LIGGETT ,  David E. KANG ,  Yu CHEN ,  Eric LEWANDOWSKI

IPC: A61K38/17 ,  A61P25/28 ,  A61K31/437 ,  A61K31/496 ,  A61K31/42

Abstract: As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.